While this may be a relatively small fraction of patients, given that roughly 250,000 new cases of invasive breast cancer are diagnosed in the U.S. annually31, this extrapolates to roughly 3000 new cases each year in which RET alterations may become potentially relevant therapeutic targets. This evidence concerns the gene RET and invasive breast carcinoma.